Phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Ka-selective inhibitor TAK-117 versus everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy
Annals of Oncology（2016）
关键词
renal clear-cell carcinoma,vegf-targeted
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要